Preparation and biomolecule conjugation of [99mTc]Tc-MAG3

Document Type : Original Article


1 Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran



Introduction: [99mTc]Tc-MAG3 is one of the routine renal radiopharmaceuticals being used in nuclear medicine centers, throughout the world. This study investigated the synthesis and 99mTc-labeling of MAG3, as well as the synthesis of the S-acetyl-MAG3-NHS complexing agent, which was used for labeling bovine serum albumin (BSA) as a protein model using technetium-99m.
Methods: S-acetyl-MAG3 was prepared by the reaction of S-acetyl thioglycolic acid and triglycine. It was also activated to its N-hydroxysuccinimide counterpart which was used for preparation of biomolecule conjugates. All compounds and intermediates were characterized by 1H NMR and LC/Mass spectroscopy.  Labeling of MAG3 with 99m-technetium was also well performed. The radiochemical purity and stability of labeled products was done by thin-layer chromatography. Also, biodistribution studies in mice was performed.
Results: The spectroscopic results confirmed the structure of compounds. The stability of [99mTc]Tc-MAG3  and [99mTc]Tc-MAG3-BSA was determined over 24h .It was found to drop from 90% to 60% and 99% to 80%,  respectively. There was no difference between serum and buffer results. Biodistribution studies for [99mTc]Tc-MAG3 confirmed renal excretion with injected dose per gram (%ID/g) kidney of 41.28 ± 4.70 , 45.63 ± 6.36 and 12.22 ± 2.83 after 1, 4 and 24h respectively.
Conclusion: In this work, the rigorous purification processes were simplified through adjustment of molar ratios of reactants and the crude product obtained with higher yield was directly used for 99mTc labeling. The prepared labeled biomolecules conjugates showed acceptable radiochemical purity and stability. MAG3 was applicable for renal imaging according to biodistribution results.


Main Subjects

  1. Fritzberg AR, Kasina S, Eshima D, Johnson DL. Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. J Nucl Med. 1986 Jan 1;27(1):111-6.
  2. Abram U, Alberto R. Technetium and rhenium: coordination chemistry and nuclear medical applications. J Braz Chem Soc. 2006;17:1486-500.
  3. Mirahmadi N, Babaei MH, Vali AM, Daha FJ, Kobarfard F, Dadashzadeh S. 99mTc-HMPAO-labeled liposomes: an investigation into the effects of some formulation factors on labeling efficiency and in vitro stability. Nucl Med Biol. 2008 Apr 1;35(3):387-92.
  4. Ram S, Buchsbaum DJ. A peptide‐based bifunctional chelating agent for 99mtc‐and 186re‐labeling of monoclonal antibodies. Cancer. 1994 Feb 1;73(S3):769-73.
  5. Lim HJ, Choi SH. Assessment of Individual Renal Function Using 99mTc-MAG3 Renography. In Vivo. 2022 Jan 1;36(1):206-11.
  6. Bryson N, Lister-James J, Jones AG, Davis WM, Davison A. Protecting groups in the preparation of thiolate complexes of technetium. Inorg Chem. 1990 Aug;29(16):2948-51.
  7. Hnatowich DJ, Winnard P, Virzi F, Fogarasi M, Sano T, Smith CL, Cantor CR, Rusckowski M. Technetium-99m labeling of DNA oligonucleotides. J Nucl Med. 1995 Dec 1;36(12):2306-14.
  8. Shi D, Zhang Y, Xu Z, Si Z, Cheng Y, Cheng D, Liu G. Noninvasive Evaluation of EGFR Expression of Digestive Tumors Using 99mTc-MAG3-Cet-F (ab) 2-Based SPECT/CT Imaging. Mol Imaging. 2022 Jun 24;2022.
  9. Wang Y, Liu G, Hnatowich DJ. Methods for MAG3 conjugation and 99mTc radiolabeling of biomolecules. Nat Protoc. 2006 Aug;1(3):1477-80.
  10. Duncan RJ, Weston PD, Wrigglesworth R. A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. Anal Biochem. 1983 Jul 1;132(1):68-73.
  11. de Sousa Lacerda CM, Ferreira IM, Dos Santos SR, de Barros AL, Fernandes SO, Cardoso VN, de Andrade AS. (1→ 3)-β-D-glucan aptamers labeled with technetium-99 m: Biodistribution and imaging in experimental models of bacterial and fungal infection. Nucl Med Bio. 2017 Mar 1;46:19-24.
  12. Wu X, Liang H, Tan Y, Yuan C, Li S, Li X, Li G, Shi Y, Zhang X. Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo. PLoS One. 2014 Mar 6;9(3):e90752.
  13. Liu Y, Liu G, Hnatowich DJ. A brief review of chelators for radiolabeling oligomers. Mater. 2010 May 14;3(5):3204-17.
  14. Du Y, Chen Z, Duan X, Yan P, Zhang C, Kang L, Wang R. 99mTc-labeled peptide targeting interleukin 13 receptor α 2 for tumor imaging in a cervical cancer mouse model. Ann Nucl Med. 2022 Apr;36(4):360-72.
  15. Bormans G, Cleynhens B, Perdieus D, De Roo M, Verbruggen A. Comparison of benzyl, benzoyl and benzamidomethyl as protective groups for mercaptoacetyltriglycine (MAG3).
    J Label Compd Radiopharm. 1989 Jan;26(1‐12):50-2.
  16. Hassanzadeh L, Chen S, Veedu RN. Radiolabeling of nucleic acid aptamers for highly sensitive disease-specific molecular imaging. Pharm. 2018 Oct 15;11(4):106.
  17. Winnard Jr P, Chang F, Rusckowski M, Mardirossian G, Hnatowich DJ. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl Med Biol. 1997 Jul 1;24(5):425-32.
  18. Bubeck B, Brandau W, Weber E, Kälble T, Parekh N, Georgi P. Pharmacokinetics of technetium-99m-MAG3 in humans. J Nucl Med. 1990 Aug 1;31(8):1285-93.
  19. Sanad MH, Rizvi SF, Farag AB. Design of novel radiotracer 99mTcN-tetrathiocarbamate as SPECT imaging agent: a preclinical study for GFR renal function. Chem Pap. 2022 Feb;76(2):1253-63.
  20. Itoh K. 99mTc-MAG3: review of pharmacokinetics, clinical application to renal diseases and quantification of renal function. Ann Nucl Med. 2001 Jun;15(3):179-90.
  21. Cao X, Xu X, Treves ST, Drubach LA, Kwatra N, Zhang M, Fahey FH, Diamond DA, Voss SD. Development and autoregulation of kidney function in children: a retrospective study using 99mTc-MAG3 renography. Pediatr Nephrol. 2022 Jan 28:1-0.
  22. Sadre Momtaz A, Safarnejad F. Effective Dose to Adult Patients Undergoing Renal Scans With 99MTC (DMSA, DTPA, EC and MAG3). Radiat Prot Dosim. 2022 Sep 22;198(16):1244-57.
  23. Jaswal AP, Hazari PP, Prakash S, Sethi P, Kaushik A, Roy BG, Kathait S, Singh B, Mishra AK. [99mTc] Tc-DTPA-Bis (cholineethylamine) as an Oncologic Tracer for the Detection of Choline Transporter (ChT) and Choline Kinase (ChK) Expression in Cancer. ACS Omega. 2022 Apr 8;7(15):12509-23.
  24. Pi Y, Zhao Z, Yang P, Cheng J, Jiang L, Wei J, Chen X, Cai H, Yi Z. Deep regression using 99mTc-DTPA dynamic renal imaging for automatic calculation of the glomerular filtration rate. Eur Radiol. 2022 Jul 7:1-9.
  25. Roberts J, Chen B, Curtis LM, Agarwal A, Sanders PW, Zinn KR. Detection of early changes in renal function using 99mTc-MAG3 imaging in a murine model of ischemia-reperfusion injury. Am J Physiol-Ren. 2007 Oct;293(4):F1408-12.
  26. Winnard Jr P, Chang F, Rusckowski M, Mardirossian G, Hnatowich DJ. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl Med Biol. 1997 Jul 1;24(5):425-32.
  27. Shabani G, Hadizad T, Najafi R. Synthesis, formulation and quality control of 99mTc-MAG3, as a renal tubular 99mTc-radiopharmaceutical kit [Persian]. Iran J Nucl Med. 2002 Nov 1;10(1):43-9.
  28. Brandau W, Bubeck B, Eisenhut M, Taylor DM. Technetium-99m labeled renal function and imaging agents: III. Synthesis of 99mTc-MAG3 and biodistribution of by-products. International Journal of Radiation Applications and Instrumentation. Part A. Appl Radiat. 1988 Jan 1;39(2):121-9.
  29. dos Santos SR, Corrêa CR, de Barros AL, Serakides R, Fernandes SO, Cardoso VN, de Andrade AS. Identification of Staphylococcus aureus infection by aptamers directly radiolabeled with technetium-99m. Nucl Med Biol. 2015 Mar 1;42(3):292-8.